Results 151 to 160 of about 2,389,287 (216)

The Progression-Free-Survival Ratio in Molecularly Aided Tumor Trials: A Critical Examination of Current Practice and Suggestions for Alternative Methods. [PDF]

Biom J
Edelmann D, Terzer T, Horak P, Schlenk R, Benner A.   +4 more
europepmc   +1 more source

Alternative Methods to Current In Vivo Procedures to Address the 3Rs Tenet in Rabies Proficiency Testing. [PDF]

Viruses, 2022
Zorzan M, Gourlaouen M, Leopardi S, De Benedictis P.   +3 more
europepmc   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Alternative Methods for Biodiesel Cetane Number Valuation: A Technical Note. [PDF]

ACS Omega
Mekonnen KD, Endris YA, Abdu KY.
europepmc   +1 more source

Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. [PDF]

Front Pharmacol, 2022
Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB.   +4 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Evaluation of alternative methods of tunnel composting (submitted by the European Composting Network) II. [PDF]

EFSA J
EFSA Panel on Biological Hazards (BIOHAZ), Koutsoumanis K, Allende A, Bolton D, Bover-Cid S, Chemaly M, Herman L, Hilbert F, Lindqvist R, Nauta M, Nonno R, Peixe L, Skandamis P, Ru G, Simmons M, De Cesare A, Escamez PF, Suffredini E, Ortiz-Pelaez A, Ordonez AA.   +19 more
europepmc   +1 more source

Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome. [PDF]

Trends Genet, 2022
Grimm NB, Lee JT.
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Classification of carotid artery plaques: promising alternative methods to computed tomography angiography through radiomics approach using neck non-contrast computed tomography. [PDF]

Quant Imaging Med Surg
Wang H, Liang Y, Song M, Zhang Z, Gu M, Mao Q, Shen F, Xin E, Liu A, Zhao H, Pan Y.   +10 more
europepmc   +1 more source